Showing results (51-60 of 185) with videos related to

Sort By:
Pageof 19
Therapeutic Advances in Endocrinology and Metabolism|April 5, 2021
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world dataTaeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
BMC Infectious Diseases|August 20, 2015
Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patientsMasanori Atsukawa, Akihito Tsubota, Noritomo Shimada, et al.
Hepatology Communications|August 30, 2022
Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitusTaeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 5, 2025
Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes MellitusTaeang Arai, Masanori Atsukawa, Chikako Nagao, et al.
Scientific Reports|October 15, 2016
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver diseaseErina Kumagai, Yohei Mano, Sachiyo Yoshio, et al.
Scientific Reports|August 6, 2021
Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver diseaseTaeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
Frontiers in Immunology|March 11, 2021
Increased Frequency of Dysfunctional Siglec-7-CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver DiseaseYuzuru Sakamoto, Sachiyo Yoshio, Hiroyoshi Doi, et al.
Cancer Medicine|December 22, 2018
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Journal of Gastroenterology|November 2, 2018
TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapyEtsuko Iio, Kentaro Matsuura, Noritomo Shimada, et al.
Alimentary Pharmacology & Therapeutics|May 4, 2026
Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects ModelsTakashi Kumada, Masanori Atsukawa, Norio Itokawa, et al.
Pageof 19